Related Experiment Video
Updated: Jul 11, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Granuloma-positive Crohn's disease
1Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, Canada. hugfree@shaw.ca
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|September 15, 2007
Summary
Epithelioid granulomas in Crohn's disease patients may indicate an early biological event. This finding can help predict disease location and behavior, aiding in early diagnosis and management.
Area of Science:
- Gastroenterology
- Histopathology
- Inflammatory Bowel Disease
Background:
- Epithelioid granulomas are a key histological finding in Crohn's disease.
- Their presence can signify a definite diagnosis in certain pathological classifications.
Purpose of the Study:
- To investigate the significance of epithelioid granulomas in Crohn's disease.
- To correlate granuloma presence with patient demographics, disease characteristics, and behavior using the Montreal classification.
Main Methods:
- Analysis of 247 Crohn's disease patients with epithelioid granulomas from a database of 1015 patients.
- Application of the Montreal classification to define age at diagnosis, disease site, and behavior in the granuloma-positive cohort.
Main Results:
- Patients with granulomas were diagnosed earlier, particularly women.
- Ileocolonic and upper GI tract involvement was common, with complex and penetrating disease behaviors observed.
- Granulomas were associated with early diagnosis, extensive disease, and complicated disease behavior.
Conclusions:
- Epithelioid granulomas may serve as a histopathological marker for early pathogenic events in Crohn's disease.
- The presence of granulomas has predictive significance for disease location and clinical behavior.
- This marker aids in understanding the etiopathogenesis and prognosis of Crohn's disease.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...